
A recent phase 3 clinical trial evaluated the effectiveness and safety of baricitinib, an oral Janus kinase inhibitor, for treating juvenile idiopathic arthritis (JIA). The trial involved 220 JIA patients from 20 countries who had an inadequate response or intolerance to conventional treatments. After a 12-week open-label lead-in period, patients who met specific response criteria were randomly assigned to receive either placebo or baricitinib in a double-blind withdrawal period. The results showed that baricitinib was significantly more effective than placebo in delaying disease flare. The medication demonstrated efficacy and an acceptable safety profile for treating various forms of JIA.
Like
Save
Share